BM
BMEA.US Biomea Fusion Inc
- Market cap
- USD 42.3M
- P/E
- -
- P/B
- 5.41x
- ROE
- -473.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BMEA.US undervalued?
Graham numberThe Graham number of Biomea Fusion Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biomea Fusion Inc fundamental analysis
No fundamental analysis for Biomea Fusion Inc yet.
Biomea Fusion Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; a…
Full company profileBiomea Fusion Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biomea Fusion Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -132K | -953K | -1.26M | -4.20M | -1.75M | -1.41M | - |
| Operating Income | -1.20M | -5.33M | -41.7M | -83.6M | -126M | -144M | -81.3M | -51.3M |
| EBITDA | -1.20M | -5.19M | -41.4M | -82.9M | -116M | -137M | -60.4M | -35.8M |
| Net Income | -1.20M | -5.32M | -41.2M | -80.0M | -117M | -138M | -61.8M | -35.9M |
| EPS | -0.11 | -0.50 | -1.73 | -2.73 | -3.44 | -3.83 | -1.18 | -0.49 |
| Balance Sheet | ||||||||
| Total Assets | 265K | 62.5M | 186M | 129M | 200M | 79.9M | 58.6M | 28.1M |
| Total Liabilities | 286K | 57.4M | 6.92M | 20.8M | 30.7M | 28.4M | 29.0M | 20.5M |
| Shareholders' Equity | -21.0K | 5.17M | 179M | 109M | 169M | 51.6M | 29.6M | 7.59M |
| Cash & Short-term Investments | 239K | 61.7M | 174M | 113M | 177M | 58.3M | 55.8M | 26.4M |
| Total Debt | - | 259K | 2.85M | 2.29M | 10.3M | 8.77M | 1.59M | 506K |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.28M | -4.46M | -35.4M | -62.4M | -96.6M | -120M | -70.4M | -40.2M |
| Capital Expenditure | 51.0K | 51.0K | 3.17M | 1.03M | 3.37M | 362K | 0.00 | 0.00 |
| Free Cash Flow | -1.28M | -4.51M | -38.6M | -63.4M | -100.0M | -120M | -70.4M | -40.2M |
| Ratios | ||||||||
| ROE | - | -103.0% | -23.1% | -73.7% | -69.3% | -268.4% | -209.1% | -473.3% |
| ROA | -452.1% | -8.5% | -22.2% | -61.9% | -58.6% | -173.2% | -105.5% | -127.8% |
| Debt to Equity | - | 0.05x | 0.02x | 0.02x | 0.06x | 0.17x | 0.05x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biomea Fusion Inc dividends
Biomea Fusion Inc has not paid dividends in the last 7 fiscal years.
Who owns Biomea Fusion Inc
- Insiders 7.29%
- Institutions 41.82%
- Public & others 50.88%
- Shares outstanding 72.7M
- Free float 67.5M
Top funds holding BMEA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 2.71M | 3.74% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.12M | 2.93% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 910K | 1.26% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 805K | 1.11% | 0.00% | Aug 2026 |
| Fidelity Select Biotechnology | 453K | 0.62% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 283K | 0.39% | -7.97% | Sep 2026 |
| iShares Micro-Cap ETF | 210K | 0.29% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 109K | 0.15% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 82.4K | 0.11% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 59.3K | 0.08% | +217.96% | Jun 2026 |
| Fidelity Nasdaq Composite Index | 39.2K | 0.05% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 37.2K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 36.5K | 0.05% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 33.2K | 0.05% | +8.37% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 32.9K | 0.05% | 0.00% | Oct 2026 |
| Fidelity ZERO Total Market Index | 28.8K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.4K | 0.02% | -49.79% | Sep 2026 |
| 1290 VT Micro Cap K | 14.1K | 0.02% | -9.69% | Sep 2026 |
| Fidelity Flex Small Cap Index | 8.61K | 0.01% | -17.18% | Aug 2026 |
| Fidelity VIP Extended Mkt Indx Initial | 5.17K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding BMEA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 8.81M | 12.16% | +0.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.83M | 3.90% | +8.96% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.05M | 2.83% | +71.02% | Jun 2026 |
| Aisling Capital Management LP | 2.05M | 2.83% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.46M | 2.01% | +10.87% | Jun 2026 |
| Fideuram - Intesa Sanpaolo Private Banking Spa | 723K | 1.00% | +29.83% | Jun 2026 |
| BlackRock Inc | 715K | 0.99% | +11.54% | Jun 2026 |
| Geode Capital Management, LLC | 709K | 0.98% | +29.31% | Jun 2026 |
| Susquehanna International Group, LLP | 613K | 0.85% | -2.72% | Jun 2026 |
| Mariner Wealth Advisors LLC | 595K | 0.82% | -9.14% | Jun 2026 |
| Jane Street Group LLC | 458K | 0.63% | +66.25% | Jun 2026 |
| UBS Group AG | 445K | 0.61% | -13.74% | Jun 2026 |
| XTX Topco Ltd | 407K | 0.56% | -23.31% | Jun 2026 |
| Two Sigma Investments LLC | 384K | 0.53% | -1.09% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 367K | 0.51% | +5.85% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 338K | 0.47% | +0.66% | Jun 2026 |
| Mccormack Advisors International | 289K | 0.40% | +224.47% | Jun 2026 |
| State Street Corp | 257K | 0.36% | +23.70% | Jun 2026 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 250K | 0.34% | 0.00% | Jun 2026 |
| Hovey Youngman Associates Inc | 248K | 0.34% | +315.36% | Sep 2026 |
Biomea Fusion Inc company profile
- Company name
- Biomea Fusion Inc
- Ticker
- BMEA.US
- Exchange
- USA Stocks
- Listed since
- Apr 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 1599 Industrial Road, San Carlos, CA, United States, 94070
- Phone
- 650 980 9099
- Website
- biomeafusion.com
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion Inc management
7- Dr. Michael J. M. Hitchcock Ph.D.Interim CEO & Director · born 1950
- Mr. Ramses M. ErdtmannCo-Founder, President, COO & Director · born 1963
- Mr. Heow TanChief Technical & Quality Officer · born 1959
- Caroline Perez- Dupont J.D.Senior Vice President of Legal
- Dr. Thorsten Kirschberg Ph.D.Executive Vice President of Research · born 1970
- Dr. Stephan Morris M.D.Chief Development Officer
- Mr. Ravi Upasani Ph.D.Executive Vice President of Intellectual Property